|
Market Closed -
NSE India S.E.
14:05:10 15/10/2026 +03
|
5-day change | 1st Jan Change | ||
| 1,764.00 INR | +1.01% |
|
-0.95% | +2.58% |
| 10-08 | Viatris Agrees to Acquire Pacira BioSciences in $1.65 Billion Deal | MT |
| 10-07 | India's Sun Pharmaceuticals to consider raising $1.55 billion via debentures | RE |
| Market Cap | 4,232B 44.53B 39.7B 36.8B 33.55B 63.19B 64.34B 443B 173B 2,203B 167B 164B 7,041B | P/E 2027 * |
32.7x | P/E 2028 * | 27.6x |
|---|---|---|---|---|---|
| Enterprise Value | 3,962B 41.69B 37.17B 34.45B 31.41B 59.16B 60.24B 414B 162B 2,062B 156B 153B 6,592B | EV / Sales 2027 * |
6.09x | EV / Sales 2028 * | 5.34x |
| Free-Float |
44.39% | Yield 2027 * |
0.97% | Yield 2028 * | 1.13% |
| Markets | Quality | ||
|---|---|---|---|
NSE India S.E.
| SUNPHARMA | Delayed | |
Bombay S.E.
| SUNPHARMA | Delayed |
Last Transcript: Sun Pharmaceutical Industries Ltd.
| 1 day | +1.01% | ||
| 1 week | -0.95% | ||
| Current month | -2.90% | ||
| 1 month | -4.13% | ||
| 3 months | -9.19% | ||
| 6 months | +6.77% | ||
| Current year | +2.58% |
| 1 week | 1,725.5 |  | 1,778 |
| 1 month | 1,725.5 | | 1,891.5 |
| Current year | 1,583.7 | | 2,046.9 |
| 1 year | 1,583.7 | | 2,046.9 |
| 3 years | 1,068.35 | | 2,046.9 |
| 5 years | 733.7 | | 2,046.9 |
| 10 years | 312 | | 2,046.9 |
| Manager | Title | Age | Since |
|---|---|---|---|
Aalok Shanghvi
CEO | Chief Executive Officer | - | - |
| Chief Executive Officer | 59 | 01/09/2025 | |
| Director of Finance/CFO | 58 | 01/07/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 70 | - | |
| Director/Board Member | 59 | 01/09/2025 | |
| Director/Board Member | 71 | 21/05/2021 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.01% | -0.95% | +6.62% | +54.02% | 44.03B | |
| +3.55% | +5.29% | +54.07% | +105.45% | 1,077B | |
| -0.25% | -2.00% | +32.71% | +61.48% | 612B | |
| +0.59% | +4.44% | +23.69% | +91.54% | 501B | |
| -1.48% | +1.68% | +71.42% | +39.59% | 364B | |
| +2.37% | +5.47% | +32.67% | +48.87% | 353B | |
| +2.64% | +4.90% | +21.01% | +43.85% | 278B | |
| +3.24% | +4.25% | -0.31% | +15.71% | 251B | |
| +1.86% | +5.07% | +47.70% | +52.77% | 230B | |
| +2.49% | +7.16% | +32.82% | +102.67% | 190B | |
| Average | +1.63% | +1.58% | +32.24% | +61.60% | 390.06B | |
| Weighted average by Cap. | +1.19% | +1.54% | +38.70% | +71.52% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 651B 6.85B 6.11B 5.66B 5.16B 9.72B 9.9B 68.07B 26.66B 339B 25.7B 25.16B 1,083B | 729B 7.67B 6.84B 6.34B 5.78B 10.89B 11.09B 76.26B 29.87B 380B 28.79B 28.19B 1,213B |
| Net income | 129B 1.36B 1.21B 1.12B 1.02B 1.93B 1.96B 13.49B 5.28B 67.14B 5.09B 4.98B 215B | 154B 1.62B 1.45B 1.34B 1.22B 2.3B 2.34B 16.11B 6.31B 80.2B 6.08B 5.95B 256B |
| Net Debt | -270B -2.84B -2.53B -2.35B -2.14B -4.03B -4.11B -28.24B -11.06B -141B -10.66B -10.44B -449B | -338B -3.56B -3.17B -2.94B -2.68B -5.05B -5.14B -35.34B -13.84B -176B -13.34B -13.06B -562B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/10/26 | ₹1,764.00 | +1.01% | 1,376,380 |
| 14/10/26 | ₹1,746.40 | -1.37% | 1,808,782 |
| 13/10/26 | ₹1,770.70 | +0.61% | 1,191,057 |
| 12/10/26 | ₹1,760.00 | 0.00% | 1,141,685 |
| 09/10/26 | ₹1,760.00 | +0.01% | 1,346,107 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- SUNPHARMA Stock
Select your edition
All financial news and data tailored to specific country editions
